Harald Wajant

27PUBLICATIONS
72CO-AUTHORS
Gene and molecular therapyBiomaterialsAutoimmunityTissue engineeringMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|May 30, 2026
A simple and broadly applicable nanobody-based approach to generate potent TNFR agonists.

|Feb 09, 2026
Biofabrication of Endothelialized, Intrinsically Vascularized 3D-Printed Recombinant Spider Silk Scaffolds.

Claire M Weinhold, Stefanie Heltmann-Meyer, Xuen J Ng

|Jan 06, 2026
TNFR2-targeting biologics: Molecular mode of action, possible applications, and future developments.

Olena Zaitseva, Harald Wajant

|Feb 25, 2025
In Vivo Vascularization of Cell-Supplemented Spider Silk-Based Hydrogels in the Arteriovenous Loop Model.

Justus Osterloh, Stefanie Heltmann-Meyer, Vanessa T Trossmann

|Jan 21, 2025
TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors.

Jennifer Wagner, David Vredevoogd, Xin Yu

|Jan 12, 2024
Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.

Nienke Hesen, Mohamed Anany, Andre Freidel

Pageof 5

Frequent Collaborators

4 joint publications

Isabell Lang

2 joint publications

Stefanie Heltmann-Meyer

2 joint publications

Dominik Steiner

2 joint publications

Thomas Scheibel